Merck Enters $2 Billion Agreement to Develop Lipoprotein(a) Inhibitor for Atherosclerosis Treatment

Merck & Co., known as MSD outside the United States and Canada, has entered into a licensing agreement valued at nearly $2 billion to advance the development of an investigational Lipoprotein(a) [Lp(a)] inhibitor. The deal aims to support the creation of a potential treatment option for patients at risk of atherosclerosis, a condition characterized by the buildup of plaque in arteries that can lead to serious cardiovascular complications.

The agreement focuses on furthering research into Lp(a), a lipoprotein linked to increased cardiovascular risk. Elevated levels of Lp(a) are associated with heightened susceptibility to conditions such as heart attacks and strokes. By targeting this specific lipoprotein, Merck seeks to address an unmet medical need for individuals who may not respond adequately to existing therapies. The financial terms underscore the company’s commitment to advancing innovative treatments in the cardiovascular space.

Date: March, 2025

Newsflash | Powered by GeneOnline AI

Related posts:

First PARP inhibitor approved for 1L maintenance therapy of BRCAm advanced ovarian cancer AbbVie Makes $350M Move into Obesity Treatment with Promising Amylin Receptor Agonist Study Reports Improved Brain Infection Diagnosis and Care in Brazil, India, and Malawi Super Bowl LIX and the Biotech Sector: A New Arena for Engagement

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後